Co-Founder and Chairman of the Investment Committee
Mr. Riggs co-founded Royalty Pharma in 1996 and assumed the role of Chairman in 2003. Mr. Riggs is also the Managing Member of Balfour Venture Partners, an investment advisor focused on mid-stage healthcare companies. From 1996 to 2000, he was President of Biomatrix, a New York Stock Exchange listed biopharmaceutical company. From 1991 to 1995, Mr. Riggs served as President and CEO of RF&P Corporation, an investment company owned by the State of Virginia Retirement System. Prior to that, Mr. Riggs spent ten years as a member of PaineWebber’s mergers and acquisitions department. Mr. Riggs graduated from Middlebury College and holds an MBA from Columbia University.
Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations. Mr. Legorreta joined Lazard Frères et Cie in Paris in 1988, then moved to Lazard Frères & Co in New York in 1990. Mr. Legorreta currently serves as a Director of Giuliani, Médica Sur, as well as a member of the Board of Trustees of The Allen-Stevenson School, the Park Avenue Armory and of the American-Austrian Foundation/Open Medical Institute. Mr. Legorreta founded and is currently Chairman the Board of Trustees of the Alianza Médica para la Salud, a privately-funded, not-for-profit foundation whose goal is to educate Mexican physicians and healthcare providers in order to improve the quality of Mexican and Latin American healthcare. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana.
Mario Germano Giuliani
Mr. Giuliani has been the President and Chief Executive Officer of Giuliani SpA, a specialty pharmaceutical company operating in Italy and established in 1942, since 2002. He previously held the title of Chief Financial Officer. During his tenure as CEO, Giuliani SpA experienced rapid growth and out-licensed several proprietary drugs, one of which was launched in the US by Shire in 2006. From January 1998 to January 1999, Mr. Giuliani was an investment professional with Vector Fund Management, a private equity firm focused on healthcare and life sciences. Mr. Giuliani also co-founded Mosaix Ventures LP, a private equity fund focused on healthcare and life sciences in 2000, and continues to serve on its Investment Committee. He also serves on several private company boards. Mr. Giuliani holds a degree in economy and commerce from the Catholic University of Sacred Heart and a Masters in corporate finance from Università Commerciale Luigi Bocconi in Milan, Italy.
Mr. Poniatowski currently serves on the Boards of Directors of Quilvest SA and International Advisory Services, and is a former non-executive Director of Quilmes Industrial SA (Luxembourg), Sociedad Iberica de Cartera, SA (Spain), Saint-Germain Investissements SA (France), Tectona (France) and Beverage Associates Corporation (BVI). Mr. Poniatowski was a senior banker with Lazard Frères in the United States and in Europe from 1976 through 2003, where he was most recently a Managing Director. While at Lazard, Mr. Poniatowski worked in the mergers and acquisitions and corporate advisory, during which time he was involved with a number of cross border assignments and transactions in Europe, the United States and Latin America. Mr. Poniatowski has a degree in financial management from Ecole des Cadres (EDC) in Paris-Neuilly, France.
Mr. Rodriguez-Pastor has been Chairman and CEO of Grupo Interbank since 1995. Interbank is one of Peru’s largest business groups with annual revenue in excess of $2 billion and 20,000 team members. Prior to returning to Peru in 1995, Mr. Rodriguez-Pastor held various management positions with Chemical Bank, PaineWebber, Citibank and Banco Santander in the US from 1983 to 1995. Mr. Rodriguez-Pastor received his BA in social sciences in 1983 from the University of California at Berkeley and his MBA in 1988 from the Amos Tuck School at Dartmouth College.
Errol De Souza, PhD
Dr. De Souza is currently the President & Chief Executive Officer of Biodel (Nasdaq: BIOD) a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. From April 2003 to January 2009, Dr. De Souza was President and Chief Executive Officer of Archemix Corporation, a biopharmaceutical company focused on aptamer therapeutics. From September 2002 to March 2003, he was President and Chief Executive Officer and a director of Synaptic Pharmaceuticals, prior to its acquisition by H. Lundbeck A/S. From 1998 to 2002, Dr. De Souza held senior management positions with Aventis and its predecessor company Hoechst Marion Roussel Pharmaceuticals, where he was Senior Vice President and Site Head of US Drug Innovation and Approval R&D, with responsibilities for the discovery and development of drug candidates for central nervous system and immunological disorders through proof-of-concept. From 1992 to 1998, he was Co-Founder and Executive Vice President of R&D at Neurocrine Biosciences, and from 1990 to 1992, Head of CNS Diseases Research at DuPont Merck. He currently serves on multiple editorial boards, NIH Committees and is on the Board of Directors of several private and public companies including Targacept Inc, (Nasdaq: TRGT), Palatin Technologies Inc (Amex: PTN) and Bionomics Limited (Australian Exchange: BNO.AX). Dr. De Souza received his BA (Honors) in physiology and his PhD in neuroendocrinology from the University of Toronto, and received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.